It's unclear how they'll weigh the findings of the career scientists at the FDA who state there's insufficient evidence to support changing the designation for any of the seven peptides under consideration
BPC-157 may accelerate the timeline for exercise progression but does not replace the need for proper rehabilitation
PubMed 18068698 TB-4 / TB-500 product mislabeling documented bidirectional mislabeling between full-length TB-4 (43 aa) and the TB-500 fragment (residues 1723) in marketed peptide products: Esposito M et al
The rapid onset of the effect, i.e., normalization of the elevated intraocular pressure, is quite consistent and fully supported in occlusion/occlusion-like syndromes research [18,19,20,21,22,23,24,25,26,27,28,29,30]